Ikris is trusted for ensuring a 100% regulatory‑compliant supply of life‑changing rare‑disease therapies not yet launched in India or emerging markets.
ACCELERATING ACCESS TO ORPHAN DRUGS
Making Orphan Drugs Reach Those Who Need Them Most
Ikris Pharma Network is proud to represent India at the World Orphan Drug Congress (WODC). We specialize in ethical and fully compliant access to unapproved global orphan medicines through the Named Patient Import Program.
Let’s connect to bridge rare disease treatment gaps and help bring life-changing therapies to patients who need them most—on time, and with care.
Be part of a global conversation on orphan drugs, rare‑disease regulatory pathways, and innovative access solutions with Ikris Pharma Network.
Ikris Pharma Network specializes in providing 100% compliant and ethical access to
unapproved or unavailable orphan therapies in India through the Named Patient Import Program.
With strong global partnerships and deep expertise in rare‑disease access, we bridge treatment
gaps and support the timely delivery of life‑saving orphan medicines.
Ikris is trusted for ensuring a 100% regulatory‑compliant supply of life‑changing rare‑disease therapies not yet launched in India or emerging markets.
We collaborate with leading orphan‑drug innovators, patient groups, and specialist institutions to improve access and support patients.
We design and manage PAPs that deliver critical therapies affordably to eligible patients, ensuring no one is left behind.
Every shipment is sourced directly from licensed manufacturers or their authorized stockists, guaranteeing genuine quality.
Fully compliant with CDSCO regulations, DGFT import permits, and WHO‑GDP standards for seamless import, distribution, and pharmacovigilance.
© Copyright 2025 -Ikris Pharma Network. All Right Reserved
1800-889-1064
Mail Us Now